⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18358867 | 1.00 | — | — | |
| SCHEMBL3064287 | 1.00 | — | — | |
| SCHEMBL18358856 | 0.92 | — | — | |
| SCHEMBL18358855 | 0.92 | — | — | |
| SCHEMBL18358863 | 0.92 | — | — | |
| SCHEMBL6624662 | 0.81 | — | — | |
| SCHEMBL132899 | 0.81 | — | — | |
| SCHEMBL4354716 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL9855170 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL9855179 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024920-A1 | ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF | HORIZON ORPHAN LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10906904-B2 | ADO-resistant cysteamine analogs and uses thereof | HORIZON ORPHAN LLC (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2017004485-A1 | ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF | RAPTOR PHARMACEUTICALS INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| CN-101595090-B | Method for preparing pleuromutilin | NABRIVA THERAPEUTICS AG | 2014-12-24 | — | — | CN | disclosed |
| US-8624033-B2 | Pleuromutilins and process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2014-01-07 | — | — | US | disclosed |
| US-20130053571-A1 | PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2013-02-28 | — | — | US | disclosed |
| US-8334389-B2 | Process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2012-12-18 | — | — | US | disclosed |
| EP-2069301-B1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2011-09-07 | — | — | EP | disclosed |
| EP-2272829-A2 | Process for the preparation of pleuromutilins | Nabriva Therapeutics AG (AT) | 2011-01-12 | — | — | EP | disclosed |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2009-10-08 | — | — | US | disclosed |
| EP-2069301-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | Nabriva Therapeutics Forschungs GmbH (AT) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008040043-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2008-04-10 | — | — | WO | disclosed |
| EP-1908750-A1 | Process for the preparation of pleuromutilins | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-04-09 | — | — | EP | disclosed |